1073P 5-year progression-free survival (PFS) with rucaparib (RUCA) maintenance in patients with newly diagnosed advanced ovarian cancer in ATHENA-MONO (GOG-3020/ENGOT-ov45)
Year: 2025
Type: article
Source: Annals of Oncology
Institutions: King's College London, Guy's and St Thomas' NHS Foundation Trust, Augusta University, City Clinical Oncology Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Intermountain Healthcare, LDS Hospital, Seoul National University Bundang Hospital, University of Turin, Kaiser Permanente Northern California, Westmead Hospital, National and Kapodistrian University of Athens, Alexandra Hospital, The US Oncology Network, Arizona Oncology, Istanbul University-Cerrahpaşa, Istanbul University, Abramson Cancer Center, University of Pennsylvania, Pomeranian Medical University, University of Kentucky, Markey Cancer Center, Charles University, Saitama International Medical Center, Saitama Medical University, Florida Cancer Specialists & Research Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415940763
FWCI:
Cites:
Cited by:
Related to: